Compounds and methods of treating ocular disorders
AssigneeCase Western Reserve University
InventorsKrzysztof Palczewski, Yu Chen
Life of this patent
Estimating the term…
Abstract
A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates at least one target in a signaling cascade associated with light induced retinal degeneration, aberrant all-trans-retinal accumulation, and/or generation of reactive oxygen species (ROS).
Claims22
A method of treating an ocular disorder associated with light induced retinal degeneration, aberrant all-trans-retinal clearance, or reactive oxygen species generation in the retina of a subject, comprising:
- administering to the subject a therapeutically effective amount of one or more agents that inhibit and/or blocks the activation of Gs- or Gq-protein coupled receptors or Gs- or Gq-signaling cascade in ocular cells of the subject, and/or activates Gi-protein coupled receptors, which is induced or triggered by light induced all-trans-retinal generation.
A method of treating geographic atrophy (GA), Stargardt disease, macular degeneration, or retinitis pigementosa in a subject, the method comprising:
- administering to the subject a therapeutically effective amount at least two or more of a Gs or Gq coupled serotonin receptor antagonist, an alpha 1 adrenergic antagonist, an alpha-2 adrenergic receptor agonist, an adenylyl cyclase inhibitor, an M3 receptor antagonist, or a PLC inhibitor.
Dependencies are inferred from the claim text.